An AllTrials project

NCT03041259: An ongoing trial by Reven Pharmaceuticals, Inc.

This trial is ongoing. It must report results 3 years from now.

Full data

Full entry on ClinicalTrials.gov NCT03041259
Title A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of Rejuveinix in Combination With Standard Interventional Therapy for Critical Limb Ischemia Patients
Results Status Ongoing
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date Jan. 31, 2020
Completion date Jan. 31, 2022
Required reporting date Jan. 31, 2023, midnight
Actual reporting date None
Date last checked at ClinicalTrials.gov Jan. 21, 2020
Days late None